Summary statistics - quantitative results

EQA round: TDM2/26 - Therapeutic Drugs

Deadline: 9.10.2026

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
N_{tot} = total number of the results
N_{out} = number of the results removed before calculation
AV = assigned value
CVP = consensus of all participants
U_{AV} = expanded uncertainty of the assigned value (k = 2)
D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
Set 1															
(81) **Digoxin**	[µg/L]				15								15	14	93
Sample A1		0,941	0,073	7,8	15		CVP	0,963	0,028	30%	0,674	1,26	15	14	93
(4) LIA, ILMA		0,963	0,085	8,8	5	0							5		
(6) Immunoturbidimetry, KIMS		0,909	0,042	4,7	5	0							5		
Other					5	0							5		
							4x 2, 1x 99								
Sample B1		1,11	0,077	7	15		CVP	1,13	0,027	30%	0,791	1,47	15	15	100
(4) LIA, ILMA		1,07	0,059	5,5	5	0							5		
(6) Immunoturbidimetry, KIMS		1,1	0,046	4,2	5	0							5		
Other					5	0							5		
							4x 2, 1x 99								
(84) **Phenobarbital**	[mg/L]				5								5	5	100
Sample A1		27,9	0,86	3,1	5		CVP	28,5	1,3	20%	22,8	34,2	5	5	100
Other					5	0							5		
							2x 2, 1x 3, 2x 6								
Sample B1		18,7	0,56	3	5		CVP	19,1	0,68	20%	15,2	23	5	5	100
Other					5	0							5		
							2x 2, 1x 3, 2x 6								
(85) **Phenytoin**	[mg/L]				1								1	1	100
Sample A1		7,11			1		CVP	6,95	0,27	20%	5,56	8,34	1	1	100
Other					1	0							1		
							1x 2								
Sample B1		22,8			1		CVP	23	0,79	20%	18,4	27,6	1	1	100
Other					1	0							1		
							1x 2								
(86) **Carbamazepin**	[mg/L]				7								7	7	100
Sample A1		12,8	0,9	7,1	7		CVP	13	0,33	20%	10,4	15,6	7	7	100
Other					7	0							7		
							3x 2, 1x 4, 3x 6								
Sample B1		10,3	1,1	11	7		CVP	10,4	0,22	20%	8,32	12,5	7	7	100
Other					7	0							7		
							3x 2, 1x 4, 3x 6								
(88) **Valproic acid**	[mg/L]				12								12	11	92
Sample A1		60,2	5	8,3	12		CVP	59,4	1	20%	47,5	71,3	12	11	92
(2) EIA (EMIT, CEDIA)		62,8	6,2	9,9	6	0							6		
(6) Immunoturbidimetry, KIMS		56,4	0,83	1,5	5	0							5		
Other					1	0							1		
							1x 4								
Sample B1		99,5	5,8	5,8	12		CVP	97,9	1,4	20%	78,3	118	12	12	100
(2) EIA (EMIT, CEDIA)		101	4,2	4,1	6	0							6		
(6) Immunoturbidimetry, KIMS		98	6	6,1	5	0							5		
Other					1	0							1		
							1x 4								
(91) **Lithium**	[mmol/L]				5								5	4	80
Sample A1													5	5	100
(5) Spectrophotometry		1,05	0,045	4,2	5	0	CVP	1,09	0,02	12%	0,959	1,23	5		
Sample B1													5	4	80
(5) Spectrophotometry		0,48	0,03	6,2	5	0	CVP	0,518	0,016	12%	0,455	0,581	5		
(82) **Theophylline**	[mg/L]				3								3	3	100
Sample A1		15,3	1,4	9,1	3		CVP	15	0,23	19%	12,1	17,9	3	3	100
Other					3	0							3		
							3x 2								
Sample B1		17	1	5,9	3		CVP	16,5	0,24	19%	13,3	19,7	3	3	100
Other					3	0							3		
							3x 2								
Set 2															
(89) **Amicacin**	[mg/L]				8								8	7	88
Sample A2		6,5	0,74	11	8		CVP	7,01	0,21	20%	5,6	8,42	8	7	88
(2) EIA (EMIT, CEDIA)		6,95	0,074	1,1	5	0							5		
Other					3	0							3		
							3x 6								
Sample B2		13,9	0,79	5,6	8		CVP	14,2	0,25	20%	11,3	17,1	8	8	100
(2) EIA (EMIT, CEDIA)		13,8	0,59	4,3	5	0							5		

Summary statistics - quantitative results

EQA round: TDM2/26 - Therapeutic Drugs

Deadline: 9.10.2026

Setup: groups - M (measurement principle); Slovakia; minimal size of the groups n = 5

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
Other					3	0	3x 6						3		
(90) **Gentamicin**	[mg/L]				14								14	13	93
Sample A2		4,17	0,68	16	14								14	13	93
(2) EIA (EMIT, CEDIA)		4,77	0,84	18	6	0	CVP	4,21	0,13	31%	2,9	5,52	6		
Other					8	0	2x 4, 3x 6, 3x 6/60						8		
Sample B2		7,68	1,3	16	14								14	14	100
(2) EIA (EMIT, CEDIA)		8,6	0,74	8,6	6	0	CVP	7,6	0,24	31%	5,24	9,96	6		
Other					8	0	2x 4, 3x 6, 3x 6/60						8		
(93) **Methotrexate**	[µmol/L]				4								4	3	75
Sample A2		0,093	0,025	27	4		CVP	0,083	0,006	30%	0,058	0,108	4	3	75
Other					4	0	1x 2, 3x 4						4		
Sample B2		3,66	0,65	18	4		CVP	3,54	0,2	30%	2,47	4,61	4	4	100
Other					4	0	1x 2, 3x 4						4		
(94) **Paracetamol**	[mg/L]				4								4	3	75
Sample A2		20,5	3,7	18	4		CVP	18,6	0,69	20%	14,8	22,4	4	3	75
Other					4	0	3x 2, 1x 99						4		
Sample B2		37,8	5,3	14	4		CVP	34,4	1,1	20%	27,5	41,3	4	3	75
Other					4	0	3x 2, 1x 99						4		
(92) **Vankomycin**	[mg/L]				16								16	16	100
Sample A2		12,8	1,3	10	16		CVP	12,8	0,28	28%	9,21	16,4	16	16	100
(2) EIA (EMIT, CEDIA)		11,9	1,1	9,4	7	0							7		
(6) Immunoturbidimetry, KIMS		13,4	0,76	5,7	8	0							8		
Other					1	0	1x 4						1		
Sample B2		29,4	3,5	12	16		CVP	29,7	0,69	28%	21,3	38,1	16	16	100
(2) EIA (EMIT, CEDIA)		27	2,4	9,1	7	0							7		
(6) Immunoturbidimetry, KIMS		31,1	2,6	8,4	8	0							8		
Other					1	0	1x 4						1		